EMR

Emerson Electric

$142.09

+3.63%
Jun 11, 2026
Bobby Quantitative Model
Emerson Electric Co. is a leading global provider of industrial automation solutions, operating within the Industrial - Machinery sector. The company has transformed from its origins as a fan manufacturer into a pure-play automation leader, offering a wide range of automation software, hardware, and power tools through segments like Intelligent Devices and Software and Systems. The current investor narrative centers on the company's strategic pivot following the divestiture of its climate technology and consumer businesses, focusing its capital and operations entirely on the high-growth industrial automation market, which is driven by long-term trends in factory digitization, productivity enhancement, and operational safety.

People also watch

Parker Hannifin

Parker Hannifin

PH

Analysis
Cummins

Cummins

CMI

Analysis
Illinois Tool Works

Illinois Tool Works

ITW

Analysis
PACCAR

PACCAR

PCAR

Analysis
Carrier Corporation

Carrier Corporation

CARR

Analysis

EMR 12-Month Price Forecast

Historical Price
Current Price $142.09
Average Target $142.09
High Target $163.40349999999998
Low Target $120.7765

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $184.72 and implied upside of +30.0% versus the current price.

Average Target

$184.72

7 analysts

Implied Upside

+30.0%

vs. current price

Analyst Count

7

covering this stock

Price Range

$114 - $185

Analyst target range

Buy
2 (29%)
Hold
3 (43%)
Sell
2 (29%)

Analyst coverage for Emerson is moderate, with data indicating 7 analysts providing estimates. The consensus sentiment appears neutral to cautiously optimistic, with recent institutional actions including a mix of reiterations and a notable downgrade from Deutsche Bank from 'Buy' to 'Hold' in early February. Specific consensus recommendation and average target price data are not available in the provided dataset, preventing a calculation of implied upside or downside. The target price range is also not specified, so the assumptions behind bullish and bearish cases cannot be quantified. The available data shows a pattern of recent analyst activity, including an upgrade by UBS from 'Neutral' to 'Buy' in January, but also a downgrade by Oppenheimer from 'Outperform' to 'Perform' later that month, reflecting ongoing debate and uncertainty regarding the stock's near-term prospects and valuation following its strategic repositioning.

Drowning in data?

Find the real signal!

EMR Technical Analysis

The stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +16.82%. Currently trading at $142.06, the price sits approximately 43% above its 52-week low of $121.56 and about 14% below its 52-week high of $165.15, positioning it in the upper-middle portion of its annual range and suggesting positive momentum without immediate overextension. Recent short-term momentum shows signs of consolidation, with a 1-month gain of +2.66% and a 3-month gain of +2.67%, which is a significant deceleration from the 1-year trend and indicates a potential pause or digestion phase after earlier strength. This divergence is further highlighted by the stock's negative relative strength versus the S&P 500 over the past one, three, and six months, signaling recent underperformance. Key technical levels are clearly defined, with immediate support near the 52-week low of $121.56 and resistance at the 52-week high of $165.15; a decisive breakout above resistance would signal a resumption of the primary uptrend, while a breakdown below support could indicate a deeper correction. The stock's beta of 1.255 confirms it is approximately 26% more volatile than the broader market, which is a critical consideration for risk management and position sizing in an industrial cyclical name.

Beta

1.25

1.25x market volatility

Max Drawdown

-23.7%

Largest decline past year

52-Week Range

$123-$165

Price range past year

Annual Return

+12.3%

Cumulative gain past year

PeriodEMR ReturnS&P 500
1m+3.5%-0.1%
3m+7.4%+11.4%
6m+4.0%+8.2%
1y+12.3%+22.7%
ytd+4.6%+8.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

EMR Fundamental Analysis

Revenue growth is positive but has shown some sequential volatility, with the most recent Q1 2026 revenue of $4.345 billion representing a 4.07% year-over-year increase from the prior-year quarter. Segment data reveals the Intelligent Devices segment is the primary growth driver, contributing $2.39 billion, followed by Software and Systems at $1.453 billion, indicating the core automation portfolio is performing. The multi-quarter trend shows revenue dipped from $4.855 billion in Q4 2025, suggesting potential near-term cyclical headwinds or seasonality impacting the growth trajectory. The company is solidly profitable, reporting net income of $605 million and a gross margin of 48.56% for Q1 2026. Profitability metrics are healthy, with a trailing net margin of 12.73% and an operating margin of 19.60%. However, the quarterly gross margin of 48.56% represents a compression from the 52.54% reported in the prior Q4, warranting close monitoring for margin sustainability amid potential cost pressures or mix shifts. The balance sheet and cash flow position is robust, characterized by a manageable debt-to-equity ratio of 0.678 and strong free cash flow generation, with TTM free cash flow of $2.575 billion. The current ratio of 0.876 indicates adequate, though not excessive, short-term liquidity. A return on equity (ROE) of 11.31% demonstrates satisfactory capital efficiency, and the substantial free cash flow provides ample internal funding for growth initiatives, dividends, and share repurchases without over-reliance on external financing.

Quarterly Revenue

$4.3B

2025-12

Revenue YoY Growth

+0.04%

YoY Comparison

Gross Margin

+0.48%

Latest Quarter

Free Cash Flow

$2.6B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Intelligent Devices
Software And Systems
Safety And Productivity

Open an Account, get $2 TSLA now!

Valuation Analysis: Is EMR Overvalued?

Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 32.20x, which is significantly higher than its forward PE of 19.86x, indicating the market expects significant earnings growth and normalization in the coming year. The large gap between trailing and forward multiples suggests the current earnings may be depressed or that analysts anticipate a sharp recovery in profitability. Compared to sector averages, Emerson's valuation presents a mixed picture; its forward PE of 19.86x is elevated relative to many industrial peers, but this premium may be justified by its focused exposure to the structurally growing automation market and its leading portfolio of software and intelligent devices. The PEG ratio of 1.77, based on the forward PE, suggests the stock is priced for growth but not egregiously so, assuming analyst growth estimates are met. Historically, the current trailing PE of 32.20x sits above the multi-quarter range observed in the historical ratios data, which has fluctuated between approximately 15x and 31x over the past two years. This positioning near the top of its own historical band suggests the market is currently pricing in optimistic expectations for the company's strategic transformation and future earnings power, leaving little room for disappointment.

PE

32.2x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 1x~98x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

17.8x

Enterprise Value Multiple